Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Beta-Blockers in Heart Attack Recovery: Reevaluating Their Role Based on Recent Research Insights
Beta-Blockers Heart Attack Research: Key Findings from Recent Meta-Analysis
Have you wondered if beta-blockers truly benefit heart attack survivors with normal heart function? Beta-blockers heart attack rese...
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions
CTX310 Breakthrough in Lipid Disorder Treatment
CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients
European Commission Approves Koselugo for Adult NF1 Patients
The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...